DNAワクチンの世界市場

DNAワクチンの世界市場は2030年までに8億5,140万米ドルに達する見込み

2024年に5億9,210万米ドルと推定されるDNAワクチンの世界市場は、2030年には8億5,140万米ドルに達し、分析期間2024～2030年のCAGRは6.2%で成長すると予測されます。本レポートで分析したセグメントの1つであるオンセプトワクチンは、CAGR 5.7％を記録し、分析期間終了時には4億4,590万米ドルに達すると予測されます。西ナイル・イノベーター・ワクチン分野の成長率は、分析期間中CAGR 7.3％と推定されます。

米国市場は1億5,560万米ドルと推定、中国はCAGR6.1％で成長予測

米国のDNAワクチン市場は、2024年に1億5,560万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年にかけてCAGR 6.1%で推移し、2030年には1億3,720万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.7%と5.3%と予測されています。欧州では、ドイツがCAGR 5.1%で成長すると予測されています。

世界のDNAワクチン市場- 主要動向と促進要因のまとめ

なぜDNAワクチンが予防医療のゲームチェンジャーとして台頭しているのか？

DNAワクチンは、安全性、安定性、適応性の強力なブレンドを提供し、従来のワクチンとは異なるユニークな利点があるため、世界のワクチン事情において急速に注目を集めています。不活化病原体やタンパク質サブユニットを使用する従来のワクチンとは異なり、DNAワクチンは目的の抗原をコードするDNA配列を含む遺伝子操作プラスミドを導入します。投与されると、宿主細胞は抗原を内部で産生し、体液性免疫応答と細胞性免疫応答の両方を刺激します。このメカニズムは自然感染をより忠実に模倣し、長期的な免疫力を高める。DNAワクチンの主な魅力のひとつは、非感染性であるため、弱毒化ワクチンで懸念される病原性復帰のリスクがないことです。また、劣化しにくいため常温保存が可能で、特に資源が限られた環境での流通が容易です。この特徴は、COVID-19パンデミックの際に特に有用であることが証明され、将来のアウトブレイクへの対応にも有望です。そのモジュール設計により、新たな亜種や異なる病原体をターゲットとする場合にも高い適応性を発揮します。世界の保健システムがパンデミックへの備えとワクチン接種の公平性を向上させようと努力する中、DNAワクチンは、ヒトと獣医の両方の疾病予防を変革できる柔軟な次世代ソリューションとして、ますます注目されています。

デリバリー技術と遺伝子工学の進歩は、DNAワクチン開発をどのように後押ししているのか？

技術革新は、歴史的にヒトにおける免疫原性の弱さという課題に直面してきたDNAワクチンの有効性とデリバリーを強化する上で極めて重要な役割を果たしています。最も重要なブレークスルーのひとつは、エレクトロポレーション（小さな電気パルスが細胞膜に一時的な孔を開け、DNAの取り込みを促進する）のような高度な送達システムの開発です。針を使わない注射器やナノ粒子キャリアも、細胞送達と患者のコンプライアンスを改善するために研究されています。さらに、コドンの最適化、強力なプロモーター、免疫刺激エレメントの組み込みなど、プラスミド設計の強化により、遺伝子発現と抗原提示が著しく向上しました。合成生物学のツールにより、ワクチン構築物の迅速な反復と改良が可能になり、開発者は進化する病原体に迅速に適応できるようになりました。CRISPRベースの遺伝子編集と計算モデリングは、強力なエピトープの同定とワクチン設計プロセスの合理化にも役立っています。さらに、DNAワクチンをアジュバントや異種プライムブーストレジメン（ウイルスベクターやタンパク質サブユニットとの組み合わせ）と統合し、免疫応答を増幅することも研究されています。このような技術革新は、前臨床での成功と臨床での有効性のギャップを埋め、DNAワクチンのヒトへの普及をより現実的なものにしています。バイオテクノロジーとバイオインフォマティクスの継続的な進歩により、DNAワクチンはこれまで以上に強力で、標的を絞った、汎用性の高いものになる軌道に乗っています。

なぜDNAワクチン市場では地域や分野によって採用パターンが異なるのか？

DNAワクチンの採用は、規制環境、公衆衛生の優先順位、技術インフラ、疾患の流行などの違いに影響され、地域や応用分野によって大きく異なります。北米、特に米国では、DNAワクチン開発は政府資金、学術研究、民間バイオテクノロジー投資によって強力に支えられてきました。この地域は、ジカ熱、HIV、COVID-19などの感染症や、前立腺がん、子宮頸がんなどをターゲットとしたヒト用ワクチンの臨床試験のパイオニアです。対照的に、アジア太平洋諸国、特にインド、中国、韓国では、DNAワクチンが家畜や家禽の口蹄疫や鳥インフルエンザなどの病気に対して使用される獣医学分野での採用が拡大しています。動物用DNAワクチンの規制経路は柔軟であることが多く、ヒトへの適用に比べ迅速な市場参入が可能です。欧州では、活発な調査が行われているもの、規制上のハードルが高く、市場承認が遅れているため、慎重な見通しが続いています。一方、ラテンアメリカとアフリカは、デング熱、チクングニア、マラリアなどの風土病に対処するDNAワクチンの可能性を秘めた新興市場であるが、限られたインフラと資金が障壁となっています。分野別では、規制の複雑性が低く、経済的利益がすぐに得られることから、現在、獣医学的応用が商業的利用の大半を占めています。しかし、安全性、有効性、社会的受容性が改善され続けているため、ヒトの健康への応用が勢いを増しています。こうした多様なパターンは、DNAワクチン採用の多面的な性質と、市場の潜在力を最大限に引き出すための地域戦略の重要性を反映しています。

DNAワクチン市場の成長を促進する主な要因は何か？

DNAワクチン市場の成長の原動力は、科学的、医学的、ロジスティックな要因の融合であり、この技術が世界の健康戦略において重要性を増していることを裏付けています。その中でも、感染症の増加、人獣共通感染症の脅威の出現、ウイルスの突然変異は、DNAワクチンが得意とする迅速で、スケーラブルで、適応性のあるワクチンプラットフォームを必要とします。COVID-19パンデミックは、核酸プラットフォームへの公共および民間投資を促進し、迅速に再プログラム化し、大規模に製造できるワクチン技術の重要な必要性を強調しました。また、DNAワクチンはmRNAワクチンに比べ、標準的な冷蔵設備だけで済むため、コールドチェーンが容易であり、実用的な予防接種ソリューションを求める中低所得国にとって非常に魅力的です。個別化医療への関心の高まりも重要な推進力であり、特にがん領域では、DNAワクチンを個々の腫瘍プロファイルに合わせて標的免疫療法を行うことができます。さらに、抗菌剤耐性に対する意識の高まりは、ワクチンのような予防的対策に改めて注目させ、ヒトと動物の両方の健康分野における市場需要を増大させています。ファスト・トラック指定やバイオテクノロジー研究への資金増額など、支援的な規制の枠組みは臨床開発と商業化をさらに加速させています。CRO（医薬品開発業務受託機関）やCMO（医薬品製造業務受託機関）の普及は、バイオテクノロジー企業の迅速なスケールアップを可能にし、政府、NGO、製薬企業間の戦略的協力関係は、公平なアクセスとイノベーションを促進しています。これらの要因が相まって、DNAワクチンは現代の免疫学と公衆衛生を変革する力として位置づけられています。

セグメント

製品タイプ（オンセプト、ウエストナイルウイルス感染症不活化ワクチン、Apex-IHN）、タイプ（治療用ワクチン、予防用ワクチン）、エンドユース（動物クリニック、動物病院）

調査対象企業の例（注目の43社）

• AnGes, Inc.
• Astellas Pharma
• Boehringer Ingelheim GmbH
• Cadila Healthcare（Zydus Cadila）
• Eurogentec S.A.
• GeneOne Life Science, Inc.
• Geovax Biologics
• Inovio Pharmaceuticals, Inc.
• Madison Vaccines Incorporated
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takara Bio Inc.
• Tekmira Pharmaceuticals（Arbutus）
• Thermo Fisher Scientific Inc.
• VGXI（subsidiary of GeneOne）
• Vical, Inc.
• Zydus Cadila（Cadila Healthcare）

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global DNA Vaccines Market to Reach US$851.4 Million by 2030

The global market for DNA Vaccines estimated at US$592.1 Million in the year 2024, is expected to reach US$851.4 Million by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Oncept Vaccines, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$445.9 Million by the end of the analysis period. Growth in the West Nile-Innovator Vaccines segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$155.6 Million While China is Forecast to Grow at 6.1% CAGR

The DNA Vaccines market in the U.S. is estimated at US$155.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$137.2 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global DNA Vaccines Market - Key Trends & Drivers Summarized

Why Are DNA Vaccines Emerging as a Game-Changer in Preventive Medicine?

DNA vaccines are rapidly gaining prominence in the global vaccine landscape due to their unique advantages over traditional vaccines, offering a powerful blend of safety, stability, and adaptability. Unlike conventional vaccines that use inactivated pathogens or protein subunits, DNA vaccines introduce genetically engineered plasmids containing the DNA sequence encoding the antigen of interest. Once administered, the host cells produce the antigen internally, thereby stimulating both humoral and cellular immune responses. This mechanism mimics natural infection more closely and enhances long-term immunity. One of the primary attractions of DNA vaccines is their non-infectious nature, eliminating the risk of reversion to virulence-a concern with live-attenuated vaccines. They are also less prone to degradation, allowing for room temperature storage and easing distribution, particularly in resource-limited settings. Moreover, DNA vaccines can be rapidly developed and manufactured at scale, a feature that proved especially valuable during the COVID-19 pandemic and holds promise for responding to future outbreaks. Their modular design makes them highly adaptable for targeting emerging variants and different pathogens altogether. As global health systems strive to improve pandemic preparedness and vaccination equity, DNA vaccines are increasingly seen as a flexible, next-generation solution capable of transforming disease prevention across both human and veterinary medicine.

How Are Advances in Delivery Technology and Genetic Engineering Fueling DNA Vaccine Development?

Technological innovation is playing a pivotal role in enhancing the efficacy and delivery of DNA vaccines, which historically faced challenges in terms of weak immunogenicity in humans. One of the most significant breakthroughs has been the development of advanced delivery systems such as electroporation, where a small electrical pulse creates temporary pores in cell membranes to facilitate DNA uptake. Needle-free injectors and nanoparticle carriers are also being explored to improve cellular delivery and patient compliance. Furthermore, enhancements in plasmid design-such as codon optimization, strong promoters, and inclusion of immune-stimulatory elements-have significantly boosted gene expression and antigen presentation. Synthetic biology tools now allow for rapid iteration and refinement of vaccine constructs, enabling developers to quickly adapt to evolving pathogens. CRISPR-based gene editing and computational modeling are also helping identify potent epitopes and streamline the vaccine design process. Additionally, the integration of DNA vaccines with adjuvants or heterologous prime-boost regimens (in combination with viral vectors or protein subunits) is being investigated to amplify immune responses. These innovations are bridging the gap between preclinical success and clinical effectiveness, making DNA vaccines more viable for widespread human use. With ongoing advancements in biotechnology and bioinformatics, DNA vaccines are on a trajectory to become more potent, targeted, and versatile than ever before.

Why Do Regional and Sectoral Adoption Patterns Vary in the DNA Vaccines Market?

Adoption of DNA vaccines varies significantly across regions and application sectors, influenced by differences in regulatory environments, public health priorities, technological infrastructure, and disease prevalence. In North America, particularly the United States, DNA vaccine development has been strongly supported by government funding, academic research, and private biotech investment. The region has been a pioneer in clinical trials for human DNA vaccines targeting infectious diseases like Zika, HIV, and COVID-19, as well as cancers such as prostate and cervical cancer. In contrast, Asia-Pacific countries-especially India, China, and South Korea-have witnessed growing adoption in the veterinary field, where DNA vaccines are used against diseases like foot-and-mouth disease and avian influenza in livestock and poultry. Regulatory pathways for veterinary DNA vaccines are often more flexible, allowing quicker market entry compared to human applications. Europe remains cautiously optimistic, with active research but stringent regulatory hurdles that slow down market approval. Meanwhile, Latin America and Africa are emerging markets where DNA vaccines hold potential for addressing endemic diseases such as dengue, chikungunya, and malaria, though limited infrastructure and funding remain barriers. Sector-wise, veterinary applications currently dominate commercial use due to lower regulatory complexity and immediate economic benefits. However, human health applications are gaining momentum as safety, efficacy, and public acceptance continue to improve. These diverse patterns reflect the multifaceted nature of DNA vaccine adoption and the importance of regional strategies in unlocking the market’s full potential.

What Are the Key Drivers Propelling Growth in the DNA Vaccines Market?

The growth in the DNA vaccines market is driven by a convergence of scientific, medical, and logistical factors that underscore the technology’s growing relevance in global health strategies. Foremost among these is the rising incidence of infectious diseases, emerging zoonotic threats, and viral mutations, which demand rapid, scalable, and adaptable vaccine platforms-areas where DNA vaccines excel. The COVID-19 pandemic underscored the critical need for vaccine technologies that can be quickly reprogrammed and manufactured at scale, driving public and private investment into nucleic acid platforms. DNA vaccines also offer a more favorable cold chain profile compared to mRNA vaccines, requiring only standard refrigeration, which makes them highly attractive for low- and middle-income countries seeking practical immunization solutions. Growing interest in personalized medicine is another key driver, particularly in oncology, where DNA vaccines can be tailored to individual tumor profiles for targeted immunotherapy. Additionally, rising awareness of antimicrobial resistance has renewed focus on preventative measures like vaccines, increasing market demand across both human and animal health sectors. Supportive regulatory frameworks, including fast-track designations and increased funding for biotechnology research, are further accelerating clinical development and commercialization. The proliferation of contract research and manufacturing organizations (CROs and CMOs) is enabling biotech firms to scale up quickly, while strategic collaborations between governments, NGOs, and pharmaceutical companies are driving equitable access and innovation. Together, these factors are positioning DNA vaccines as a transformative force in modern immunology and public health.

SCOPE OF STUDY:

The report analyzes the DNA Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Oncept, West Nile-Innovator, Apex-IHN); Type (Therapeutic Vaccines, Prophylactic Vaccines); End-Use (Veterinary Clinics, Veterinary Hospitals)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

• AnGes, Inc.
• Astellas Pharma
• Boehringer Ingelheim GmbH
• Cadila Healthcare (Zydus Cadila)
• Eurogentec S.A.
• GeneOne Life Science, Inc.
• Geovax Biologics
• Inovio Pharmaceuticals, Inc.
• Madison Vaccines Incorporated
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takara Bio Inc.
• Tekmira Pharmaceuticals (Arbutus)
• Thermo Fisher Scientific Inc.
• VGXI (subsidiary of GeneOne)
• Vical, Inc.
• Zydus Cadila (Cadila Healthcare)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • DNA Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Global Immunization Initiatives Throw the Spotlight on DNA Vaccines as Next-Gen Platforms
  • Pandemic-Driven R&D Acceleration Propels Growth in Nucleic Acid-Based Vaccine Technologies
  • Rapid Design and Scalability Advantages Accelerate Demand for DNA Vaccine Development
  • Here's How Advances in Electroporation Devices Drive Delivery Efficiency in DNA Immunization
  • Zoonotic Disease Outbreaks Expand Application Pipeline for Veterinary DNA Vaccines
  • Growing Interest in Personalized Immunotherapies Spurs Investment in DNA Vaccine Platforms
  • Cold-Chain Independent Storage Capabilities Generate Opportunities in Remote Healthcare Delivery
  • Rise in Biodefense Funding Globally Sustains Strategic Demand for DNA Vaccine Stockpiling
  • Breakthroughs in Synthetic Biology Fuel Innovation in Multivalent DNA Constructs
  • Here's the Story: Oncology Vaccine Pipelines Drive Market for Tumor-Specific DNA Therapies
  • Integration with Adjuvant Technologies Enhances Immunogenicity of DNA-Based Formulations
  • Emerging Infectious Disease Threats Expand Market Scope for Rapid-Response DNA Platforms
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World DNA Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for DNA Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for DNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Oncept by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Oncept by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for West Nile-Innovator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for West Nile-Innovator by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Apex-IHN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Apex-IHN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Therapeutic Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Therapeutic Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Prophylactic Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Veterinary Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Veterinary Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Veterinary Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Veterinary Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • DNA Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 18: USA Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 19: USA 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 20: USA Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 22: USA Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 23: USA 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030
• CANADA
  • TABLE 24: Canada Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 25: Canada 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 26: Canada Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Canada 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 28: Canada Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Canada 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030
• JAPAN
  • DNA Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 30: Japan Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Japan 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 32: Japan Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Japan 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 34: Japan Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Japan 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030
• CHINA
  • DNA Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 36: China Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 37: China 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 38: China Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: China 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 40: China Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 41: China 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030
• EUROPE
  • DNA Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 42: Europe Recent Past, Current & Future Analysis for DNA Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 43: Europe 6-Year Perspective for DNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 44: Europe Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Europe 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 46: Europe Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Europe 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 48: Europe Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Europe 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030
• FRANCE
  • DNA Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 50: France Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: France 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 52: France Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 53: France 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 54: France Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 55: France 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030
• GERMANY
  • DNA Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 56: Germany Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Germany 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 58: Germany Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Germany 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 60: Germany Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Germany 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030
• ITALY
  • TABLE 62: Italy Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Italy 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 64: Italy Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Italy 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 66: Italy Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Italy 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030
• UNITED KINGDOM
  • DNA Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 68: UK Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: UK 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 70: UK Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 71: UK 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 72: UK Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 73: UK 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Rest of Europe 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 77: Rest of Europe 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 79: Rest of Europe 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030
• ASIA-PACIFIC
  • DNA Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Asia-Pacific 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Asia-Pacific 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Asia-Pacific 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 86: Rest of World Recent Past, Current & Future Analysis for DNA Vaccines by Product Type - Oncept, West Nile-Innovator and Apex-IHN - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of World 6-Year Perspective for DNA Vaccines by Product Type - Percentage Breakdown of Value Sales for Oncept, West Nile-Innovator and Apex-IHN for the Years 2025 & 2030
  • TABLE 88: Rest of World Recent Past, Current & Future Analysis for DNA Vaccines by Type - Therapeutic Vaccines and Prophylactic Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Rest of World 6-Year Perspective for DNA Vaccines by Type - Percentage Breakdown of Value Sales for Therapeutic Vaccines and Prophylactic Vaccines for the Years 2025 & 2030
  • TABLE 90: Rest of World Recent Past, Current & Future Analysis for DNA Vaccines by End-Use - Veterinary Clinics and Veterinary Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Rest of World 6-Year Perspective for DNA Vaccines by End-Use - Percentage Breakdown of Value Sales for Veterinary Clinics and Veterinary Hospitals for the Years 2025 & 2030

IV. COMPETITION